Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Fast-acting Insulin Aspart 200 U/mL Formulations in T1DM
NCT03723759Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2018
- Primary completion
- Mar 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised trial of faster-acting insulin aspart in type 1 diabetes mellitus (T1D) (6 arms), sponsored by Novo Nordisk. Primary endpoint: Area under the serum insulin aspart concentration-time curve from 0 to t hours. Started Oct 2018; status: completed.
02
Drugs
faster-acting insulin aspart
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03723759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03723759.